FREDUN PHARMACEUTICALS L (FREDUN) financials

FREDUN PHARMACEUTICALS L (FREDUN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1987, Fredun PharmaceuticalsLtd manufactures & exports healthcare and pharmaceuticals products[1]

Market Cap: ₹2,315Cr.
Current Price: ₹1,404
Stock P/E: 52.1
ROE: 15.8%
ROCE: 21.5%
Book Value: ₹170
Dividend Yield: 0.02%
52W High / Low: ₹1,600/427

In Jun 2026, FREDUN PHARMACEUTICALS L (FREDUN) reported sales ₹228 Cr and net profit ₹13 Cr.

Annual TTM: sales ₹748 Cr, net profit ₹44 Cr.

Shareholding: Promoters 44.57% (Jul 2026), FIIs 1.06% (Jul 2026), DIIs 2.94% (Jul 2026), Public 51.43% (Jul 2026), No. of Shareholders 9,598% (Jul 2026).

FREDUN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	107	103	167	120	145	161	213	228
Expenses	93	89	150	103	123	135	184	195
Operating Profit	14	13	17	17	22	26	29	33
OPM %	13%	13%	10%	14%	15%	16%	14%	14%
Other Income	0	0	0	0	0	0	0	0
Interest	5	5	8	7	8	11	14	9
Depreciation	1	1	1	1	2	2	3	4
Profit before tax	8	7	8	9	13	14	12	21
Tax %	44%	25%	12%	25%	25%	25%	4%	36%
Net Profit	4	5	7	7	10	10	11	13
EPS in Rs	3.01	3.75	4.98	4.77	6.85	6.51	6.75	7.98
Raw PDF	—	—	—	—	—	—	—	—

FREDUN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	113	134	222	275	348	454	635	748
Expenses	104	126	208	247	310	401	544	637
Operating Profit	8	8	14	28	38	53	91	111
OPM %	7%	6%	6%	10%	11%	12%	14%	15%
Other Income	1	1	2	2	1	2	4	0
Interest	4	4	5	9	14	22	39	41
Depreciation	2	2	2	3	4	4	8	10
Profit before tax	2	3	9	18	21	28	48	59
Tax %	24%	37%	26%	38%	27%	26%	30%	—
Net Profit	2	2	6	11	16	21	33	44
EPS in Rs	1.58	1.68	4.77	7.95	11.08	14.65	20.25	28.09
Dividend Payout %	14%	14%	5%	3%	2%	2%	1%	—

FREDUN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4	4	4	4	5	5	5	5
Reserves	35	37	39	64	92	117	137	273
Borrowings	19	35	40	53	87	106	166	222
Other Liabilities	47	65	79	66	74	81	179	141
Total Liabilities	105	141	162	187	257	308	487	642
Fixed Assets	31	31	30	32	39	47	53	118
CWIP	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	1	2	2
Other Assets	74	110	131	155	218	260	433	522
Total Assets	105	141	162	187	257	308	487	642

FREDUN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	1	-11	0	-2	-14	-0	-21	16
Cash from Investing Activity	-5	-1	-1	-4	-9	-8	-6	-74
Cash from Financing Activity	4	14	-1	7	25	6	26	122
Net Cash Flow	0	2	-2	1	1	-2	-1	65
Free Cash Flow	-4	-12	-1	-7	-24	-8	-27	-57
CFO/OP	8%	-128%	2%	-17%	-52%	-1%	-43%	18%

FREDUN shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026
Promoters	48.93%	48.93%	48.93%	48.93%	43.06%	44.17%	44.57%	44.57%
FIIs	0.00%	0.00%	0.00%	0.01%	0.46%	1.06%	1.06%	1.06%
DIIs	1.59%	1.59%	1.59%	1.61%	3.48%	2.83%	2.94%	2.94%
Public	49.47%	49.47%	49.49%	49.46%	53.00%	51.94%	51.45%	51.43%
No. of Shareholders	8,121	7,976	7,906	8,120	8,765	8,338	8,903	9,598

FREDUN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	67	126	112	148	46	68	142	53
Inventory Days	249	227	242	96	264	246	267	219
Days Payable	205	208	215	101	104	88	161	71
Cash Conversion Cycle	110	145	139	144	205	225	248	201
Working Capital Days	66	65	116	126	97	92	76	79
ROCE %	21%	10%	10%	13%	18%	17%	19%	21%

FREDUNUpdated 1 Oct 2026, 2:18

Fredun Pharmaceuticals L

FREDUNUpdated 1 Oct 2026, 2:18

Market Cap

₹2,315Cr.

Current Price

₹1,404

High / Low

₹1,600/427

Stock P/E

52.1

ROE15.8%

ROCE21.5%

Book Value₹170

Face Value₹10.0

Dividend Yield0.02%

About

Incorporated in 1987, Fredun PharmaceuticalsLtd manufactures & exports healthcare and pharmaceuticals products[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	62	3	54	1	4	41	2	1.75
Sep 2023	82	3	72	1	6	32	4	2.79
Dec 2023	87	4	76	1	6	27	4	2.99
Mar 2024	118	4	107	1	6	13	5	3.59
Jun 2024	79	4	68	1	6	25	4	2.91
Sep 2024	107	5	93	1	8	44	4	3.01
Dec 2024	103	5	89	1	7	25	5	3.75
Mar 2025	167	8	150	1	8	12	7	4.98
Jun 2025	120	7	103	1	9	25	7	4.77
Sep 2025	145	8	123	2	13	25	10	6.85
Dec 2025	161	11	135	2	14	25	10	6.51
Mar 2026	213	14	184	3	12	4	11	6.75
Jun 2026	228	9	195	4	21	36	13	7.98

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	25	1	24	0	1	1	52	0	0.37
Mar 2016	42	2	38	1	1	2	42	1	1.51
Mar 2017	57	2	53	2	1	2	36	1	2.01
Mar 2018	60	2	54	0	1	3	34	2	1.7
Mar 2019	97	3	87	0	1	6	28	4	3.72
Mar 2020	113	4	104	1	2	2	24	2	1.58
Mar 2021	134	4	126	1	2	3	37	2	1.68
Mar 2022	222	5	208	2	2	9	26	6	4.77
Mar 2023	275	9	247	2	3	18	38	11	7.95
Mar 2024	348	14	310	1	4	21	27	16	11.08
Mar 2025	454	22	401	2	4	28	26	21	14.65
Mar 2026	635	39	544	4	8	48	30	33	20.25
TTM	748	41	637	0	10	59	—	44	28.09

Shareholding pattern

As of Jul 2026%

Holder	Share
Promoters	44.57%
FIIs	1.06%
DIIs	2.94%
Public	51.43%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	49.16%	0%	1.6%	49.24%
Mar 2024	49.17%	0%	1.6%	49.24%
Jun 2024	49.17%	0%	1.6%	49.23%
Sep 2024	48.93%	0%	1.59%	49.47%
Dec 2024	48.93%	0%	1.59%	49.47%
Mar 2025	48.93%	0%	1.59%	49.47%
Jun 2025	48.93%	0%	1.59%	49.49%
Sep 2025	48.93%	0.01%	1.61%	49.46%
Dec 2025	43.06%	0.46%	3.48%	53%
Mar 2026	44.17%	1.06%	2.83%	51.94%
Jun 2026	44.57%	1.06%	2.94%	51.45%
Jul 2026	44.57%	1.06%	2.94%	51.43%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	2	0	9	11	23	8	1	0	14	23
Mar 2016	2	1	16	24	43	15	0	0	29	43
Mar 2017	2	2	21	30	56	16	4	0	36	56
Mar 2018	3	19	10	47	79	16	11	0	52	79
Mar 2019	4	35	19	47	105	31	0	0	74	105
Mar 2020	4	37	35	65	141	31	0	0	110	141
Mar 2021	4	39	40	79	162	30	0	0	131	162
Mar 2022	4	64	53	66	187	32	0	0	155	187
Mar 2023	5	92	87	74	257	39	0	0	218	257
Mar 2024	5	117	106	81	308	47	0	1	260	308
Mar 2025	5	137	166	179	487	53	0	2	433	487
Mar 2026	5	273	222	141	642	118	0	2	522	642

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	2	-3	1	0
Mar 2016	3	-6	3	1
Mar 2017	4	-7	3	-1
Mar 2018	17	-8	-8	1
Mar 2019	1	-5	4	0
Mar 2020	-11	-1	14	2
Mar 2021	0	-1	-1	-2
Mar 2022	-2	-4	7	1
Mar 2023	-14	-9	25	1
Mar 2024	0	-8	6	-2
Mar 2025	-21	-6	26	-1
Mar 2026	16	-74	122	65

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	75	98	131	94	67	126	112	148	46	68	142	53
Inventory Days	102	140	68	170	249	227	242	96	264	246	267	219
Days Payable	167	221	224	360	205	208	215	101	104	88	161	71
Cash Conversion Cycle	11	17	-24	-96	110	145	139	144	205	225	248	201
Working Capital Days	-54	-44	-39	42	66	65	116	126	97	92	76	79
ROCE %	14%	25%	18%	16%	21%	10%	10%	13%	18%	17%	19%	21%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of FREDUN PHARMACEUTICALS L (FREDUN)?

The reported market capitalisation for FREDUN PHARMACEUTICALS L (FREDUN) is ₹2,315Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of FREDUN?

The current price shown for FREDUN PHARMACEUTICALS L (FREDUN) on Fincrux is ₹1,404 with a 52-week high/low of ₹1,600/427.

What is the P/E ratio of FREDUN PHARMACEUTICALS L (FREDUN)?

The stock P/E for FREDUN PHARMACEUTICALS L (FREDUN) is 52.1 on Fincrux, with ROE at 15.8% and ROCE at 21.5%.

What were FREDUN latest quarterly results?

For Jun 2026, FREDUN PHARMACEUTICALS L (FREDUN) reported sales ₹228 Cr and net profit ₹13 Cr (figures in ₹ crore unless noted).

What are FREDUN annual sales and net profit?

For TTM, FREDUN PHARMACEUTICALS L (FREDUN) shows sales of ₹748 Cr and net profit of ₹44 Cr on the Fincrux profit & loss statement.

Who owns FREDUN PHARMACEUTICALS L (FREDUN)?

Latest shareholding for FREDUN PHARMACEUTICALS L (FREDUN) on Fincrux: Promoters 44.57% (Jul 2026), FIIs 1.06% (Jul 2026), DIIs 2.94% (Jul 2026), Public 51.43% (Jul 2026), No. of Shareholders 9,598% (Jul 2026).

Where can I find FREDUN PHARMACEUTICALS L (FREDUN) financials?

FREDUN PHARMACEUTICALS L (FREDUN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show FREDUN balance sheet and cash flow?

Yes. The FREDUN PHARMACEUTICALS L (FREDUN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 1 October 2026 at 2:18